AMC Health Partners with Icahn School of Medicine on Televideo-Enabled Prostate Cancer Clinical Trial

 

NEW YORK, Nov. 12, 2014-- Today, AMC Health announced the first patient enrolled in a prostate cancer clinical trial deploying televideo, at Mount Sinai's Icahn School of Medicine in Manhattan. The trial is testing whether the antidiabetic medication metformin may slow the progression of recurrent prostate cancer. AMC Health, a leading provider of proven mobile health solutions, has pioneered the use of televideo in clinical trials and is providing this capability for the study.

Matthew Galsky, M.D., Associate Professor of Medicine at Icahn School of Medicine, Director of Genitourinary Medical Oncology at Tisch Cancer Center at Mount Sinai and the principal investigator, said, "Our prior research demonstrates that geographic barriers and travel burdens prevent many patients from participating in clinical trials. This televideo technology by AMC Health provides a solution, connecting patients remotely with our study site. Patients living at great distances from Mount Sinai may come for an initial visit, but may be unable to travel monthly for follow-up visits, preventing them from participating in clinical trials. 'Video visits' make their participation possible."

The protocol for the trial was developed with input from patients, physicians and researchers, using an innovative crowd-sourcing platform developed by Transparency Life Sciences, a New York-based open-source pharmaceutical development company. "I developed a draft protocol," Dr. Galsky explained, "and 'the crowd' used Transparency's Internet platform to make significant improvements to the trial design."

"This study introduces innovative technologies that can improve future clinical trials," according to John Holland, Senior VP for Research in the Clinical Trials Division of AMC Health, "and we are honored to partner with Dr. Galsky and Mount Sinai in this effort."

Tweet This: Innovative #ClinicalTrial creates possible new treatment for prostate #cancer |http://bit.ly/1tE5k7o @AMCHealth @MountSinaiNYC #telehealth

About AMC Health 

AMC Health is a leading provider of customized, scalable, cost-effective "real-time" patient management solutions that assist organizations serving at-risk populations or that conduct clinical trials. Its patient engagement, health monitoring and care coordination solutions have been proven in several studies published in peer-reviewed journals to improve patient outcomes and quality of care, and reduce overall healthcare costs. Its Clinical Trials Division provides mobile health solutions for clinical trials. AMC Health is headquartered in New York City.  For more information, visit www.amchealth.com.

About the Mount Sinai Health System

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community‐based facilities to tertiary and quaternary care.

The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.

For more information, visit http://www.mountsinai.org, or find Mount Sinai on Facebook, Twitter and YouTube.

Around the web

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Trimed Popup
Trimed Popup